We investigated the association between platelet-to-lymphocyte ratio (PLR) and clinical outcomes (including all-cause mortality, recurrent myocardial infarction, heart failure, serious cardiac arrhythmias and ischemic stroke) in patients with ST-segment elevation myocardial infarction (STEMI). Based on PLR quartiles, 5886 patients with STEMI were categorized into 4 groups: <98.8 (n = 1470), 98.8 to 125.9 (n = 1474), 126.0 to 163.3 (n = 1478), >163.3 (n = 1464), respectively. We used Cox proportional hazards models to examine the relation between PLR and clinical outcomes. Mean duration of follow-up was 81.6 months, and 948 patients (16.1%) died during follow-up. The lowest mortality occurred in the lowest PLR quartile group (P = 0.006), with an adjusted hazard ratio of 1.18 (95% confidence interval [CI], 1.04-1.55), 1.31 (95% CI, 1.18-1.64), and 1.59 (95% CI, 1.33-1.94) in patients with PLR of 98.8 to 125.9, 126.0 to 163.3, >163.3, respectively. Higher levels of PLR were also associated with recurrent myocardial infarction (Ptrend = .023), heart failure (Ptrend = .018), and ischemic stroke (Ptrend = .043). In conclusion, a higher PLR was associated with recurrent myocardial infarction, heart failure, ischemic stroke, and all-cause mortality in patients with STEMI.
MohlenkampSLehmannNMoebusS. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–1464.
2.
IbrahimHSchuttRCHannawiBDeLaoTBarkerCMKleimanNS. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol. 2014;64(20):2122–2129.
3.
VeldersMAWallentinLBeckerRC. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the platelet inhibition and patient outcomes trial. Am Heart J. 2015;169(6):879–889.
4.
NunezJSanchisJBodiV. Therapeutic implications of low lymphocyte count in non-ST segment elevation acute coronary syndromes. Eur J Intern Med. 2009;20(8):768–774.
5.
AghdaiiNFerasatkishRMohammadzadeh JouryabiAHamidiSH. Significance of preoperative total lymphocyte count as a prognostic criterion in adult cardiac surgery. Anesth Pain Med. 2014;4(3):e20331.
6.
BaltaSOzturkC. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015;26(7):680–681.
7.
ThygesenKAlpertJSJaffeAS. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60(16):1581–1598.
8.
YancyCWJessupMBozkurtB. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–e239.
9.
PrioriSGBlomstrom-LundqvistCMazzantiA. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015;17(11):1601–1687.
10.
PowersWJDerdeynCPBillerJ. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–3035.
11.
HanssonGK. Inflammation atherosclerosis and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
van DiepenSVavalleJPNewbyLK. The systemic inflammatory response syndrome in patients with st-segment elevation myocardial infarction. Crit Care Med. 2013;41(9):2080–2087.
14.
ZouridakisEGGarcia-MollXKaskiJC. Usefulness of the blood lymphocyte count in predicting recurrent instability and death in patients with unstable angina pectoris. Am J Cardiol. 2000;86(4):449–451.
15.
TempletonAJAceOMcNamaraMG. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–1212.
16.
YaylaCCanpolatUAkyelA. Association between platelet to lymphocyte ratio and saphenous vein graft disease. Angiology. 2016;67(2):133–138.
17.
YaylaCAkbogaMKCanpolatU. The association of the platelet-to-lymphocyte ratio with mitral annular calcification. Scand Cardiovasc J. 2015;49(6):351–356.
18.
TurkmenKErdurFMOzcicekF. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17(3):391–396.
19.
KuznikBIVitkovskyYAGvozdevaOVSolpovAVMagenE. Lymphocyte-platelet crosstalk in graves’ disease. Am J Med Sci. 2014;347(3):206–210.
20.
KoseogluHIAltunkasFKanbayADorukSEtikanIDemirO. Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis. 2015;39(2):179–185.
21.
AkbogaMKCanpolatUYukselM. Platelet to lymphocyte ratio as a novel indicator of inflammation is correlated with the severity of metabolic syndrome: a single center large-scale study. Platelets. 2016;27(2):178–183.
22.
AkbogaMKCanpolatUYaylaC. Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in patients with stable coronary artery disease. Angiology. 2016;67(1):89–95.
23.
BalciKGBalciMMSenF. The role of baseline indirect inflammatory markers in prediction of response to cardiac resynchronisation therapy. Kardiol Pol. 2016;74(2):119–126.
24.
KurtulAYarliogluesMMuratSN. Usefulness of the platelet-to-lymphocyte ratio in predicting angiographic reflow after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction. Am J Cardiol. 2014;114(3):342–347.
25.
AkbogaMKYaylaCCanpolatUArasD. Platelet to lymphocyte ratio: a novel and simple predictor of slow coronary flow. Anatol J Cardiol. 2015;15(8):679.
26.
AkbogaMKCanpolatUBalciKG. Increased platelet to lymphocyte ratio is related to slow coronary flow. Angiology. 2016;67(1):21–26.
27.
KurtulAMuratSNYarliogluesM. Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in patients with acute coronary syndromes. Am J Cardiol. 2014;114(7):972–978.
28.
YaylaCAkbogaMKCanpolatU. Platelet to lymphocyte ratio can be a predictor of infarct-related artery patency in patients with ST-segment elevation myocardial infarction. Angiology. 2015;66(9):831–836.
29.
YilmazSSenFUnalS. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis. Scand Cardiovasc J. 2015;49(1):39–44.
30.
DemircelikMBKurtulAOcekHCakmakMUreyenCEryonucuB. Association between platelet-to-lymphocyte ratio and contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Cardiorenal Med. 2015;5(2):96–104.
31.
Ozcan CetinEHCetinMSArasD. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in ST-Segment elevation myocardial infarction. Angiology. 2016;67(4):336–345.
32.
AkkayaEGulMUgurM. Platelet to lymphocyte ratio: A simple and valuable prognostic marker for acute coronary syndrome. Int J Cardiol. 2014;177(2):597–598.
33.
UgurMGulMBozbayM. The relationship between platelet to lymphocyte ratio and the clinical outcomes in ST elevation myocardial infarction underwent primary coronary intervention. Blood Coagul Fibrinolysis. 2014;25(8):806–811.
34.
CicekGAcikgozSKBozbayM. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio combination can predict prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology. 2015;66(5):441–447.
